BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

509 related articles for article (PubMed ID: 15659107)

  • 1. Recombinant bispecific antibodies for cancer therapy.
    Kontermann RE
    Acta Pharmacol Sin; 2005 Jan; 26(1):1-9. PubMed ID: 15659107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bispecific antibodies for cancer therapy.
    Chames P; Baty D
    Curr Opin Drug Discov Devel; 2009 Mar; 12(2):276-83. PubMed ID: 19333873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recombinant bispecific antibodies for cellular cancer immunotherapy.
    Müller D; Kontermann RE
    Curr Opin Mol Ther; 2007 Aug; 9(4):319-26. PubMed ID: 17694444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current perspectives of bispecific antibody-based immunotherapy.
    Talac R; Nelson H
    J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advances in the generation of bispecific antibodies for tumor immunotherapy.
    Kipriyanov SM; Le Gall F
    Curr Opin Drug Discov Devel; 2004 Mar; 7(2):233-42. PubMed ID: 15603258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabodies: molecular engineering and therapeutic applications.
    Wu C
    Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative molecular formats and therapeutic applications for bispecific antibodies.
    Spiess C; Zhai Q; Carter PJ
    Mol Immunol; 2015 Oct; 67(2 Pt A):95-106. PubMed ID: 25637431
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bispecific tandem diabody for tumor therapy with improved antigen binding and pharmacokinetics.
    Kipriyanov SM; Moldenhauer G; Schuhmacher J; Cochlovius B; Von der Lieth CW; Matys ER; Little M
    J Mol Biol; 1999 Oct; 293(1):41-56. PubMed ID: 10512714
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bi-specific antibody therapy for the treatment of cancer.
    Withoff S; Helfrich W; de Leij LF; Molema G
    Curr Opin Mol Ther; 2001 Feb; 3(1):53-62. PubMed ID: 11249732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bispecific antibodies for cancer therapy.
    Hollander N
    Immunotherapy; 2009 Mar; 1(2):211-22. PubMed ID: 20635943
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bispecific T-cell engaging antibodies for cancer therapy.
    Baeuerle PA; Reinhardt C
    Cancer Res; 2009 Jun; 69(12):4941-4. PubMed ID: 19509221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bispecific antibodies for polyclonal T-cell engagement.
    Baeuerle PA; Kufer P; Lutterbüse R
    Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bispecific antibodies for cancer immunotherapy: Current perspectives.
    Müller D; Kontermann RE
    BioDrugs; 2010 Apr; 24(2):89-98. PubMed ID: 20199124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cells.
    Kellner C; Bruenke J; Stieglmaier J; Schwemmlein M; Schwenkert M; Singer H; Mentz K; Peipp M; Lang P; Oduncu F; Stockmeyer B; Fey GH
    J Immunother; 2008; 31(9):871-84. PubMed ID: 18833000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific antibodies targeting cancer cells.
    Peipp M; Valerius T
    Biochem Soc Trans; 2002 Aug; 30(4):507-11. PubMed ID: 12196124
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of bispecific and tandem diabodies.
    Kipriyanov SM
    Methods Mol Biol; 2009; 562():177-93. PubMed ID: 19554296
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Redirection of T-cell effector functions for cancer therapy: bispecific antibodies and chimeric antigen receptors.
    Satta A; Mezzanzanica D; Turatti F; Canevari S; Figini M
    Future Oncol; 2013 Apr; 9(4):527-39. PubMed ID: 23560375
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cancer therapy by using bispecific antibody].
    Azuma A; Niitani H; Okumura K
    Gan To Kagaku Ryoho; 1991 Aug; 18(10):1535-42. PubMed ID: 1872618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.